These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23391905)

  • 21. Intensification of cataleptic response in 6-hydroxydopamine-induced neurodegeneration of substantia nigra is not dependent on the degree of dopamine depletion.
    Srinivasan J; Schmidt WJ
    Synapse; 2004 Mar; 51(3):213-8. PubMed ID: 14666519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors.
    Juszkiewicz M; Chodkowska A; Burzynski SR; Mlynarczyk M; Kleinrok Z
    Drugs Exp Clin Res; 1995; 21(4):153-6. PubMed ID: 8529528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
    J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
    Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
    Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
    St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
    Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
    Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
    Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of different doses of levodopa on paraquat-induced neurotoxicity: an experiment with mice].
    Du YL; Liu ZG; Chen SD; Lu GQ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(34):2400-3. PubMed ID: 16321246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention.
    Oranje B; Gispen-de Wied CC; Westenberg HG; Kemner C; Verbaten MN; Kahn RS
    J Psychopharmacol; 2006 Nov; 20(6):789-98. PubMed ID: 16478755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
    Ferger B; Buck K; Shimasaki M; Koros E; Voehringer P; Buerger E
    Synapse; 2010 Jul; 64(7):533-41. PubMed ID: 20196139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
    Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
    Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
    J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of bromocriptine on dopamine turnover with or without levodopa.
    Ogawa N; Asanuma M; Tanaka K; Matsuura K; Iida K; Yamamoto M
    J Int Med Res; 1996; 24(3):271-7. PubMed ID: 8725988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats.
    Naeem S; Najam R; Khan SS; Mirza T; Sikandar B
    Metab Brain Dis; 2019 Aug; 34(4):1191-1199. PubMed ID: 31055785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.